From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13 ...

Ocrelizumab and rituximab, both anti-CD20 B-cell monoclonal antibodies, differ in molecular structure and safety profiles, impacting MS treatment outcomes. Retrospective data from the University of ...

Primary nephrotic syndrome in adults is characterized by severe proteinuria and hypoalbuminemia. This was the first clinical trial to test rituximab in adult-onset frequently relapsing nephrotic ...

Please provide your email address to receive an email when new articles are posted on . Results of a study showed that antirituximab antibodies are common among patients with pemphigus who have been ...

In 1975, Georges Köhler and César Milstein, biochemists from the Medical Research Council Laboratory of Molecular Biology, published a paper in Nature about a hybridoma technology that enabled the ...

Humoral rejection is refractory to conventional high-dose corticosteroid pulse therapy and invariably requires the addition of depleting antibodies, either polyclonal antilymphocyte agents or OKT3.

Over the past few years, there has been considerable progress defining the potential role of B cells in normal immunity and also in the pathogenesis of autoimmune conditions including rheumatoid ...

While limited data suggest loncastuximab tesirine plus rituximab may be active in the third line, larger cohorts and longer-term data are needed to definitively determine its effectiveness.

When you have lupus, your body’s immune system turns against your healthy tissue and organs, such as skin, joints, brain, heart, lungs, and kidneys. One of the newer treatments for lupus, called ...